Search research articles
Contact Us
Filters
Showing results (91-100 of 105) with videos related to
Page
of 11
Sort By:
Dermatology and Therapy
|
March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
Kim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Dermatology and Therapy
|
June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis
Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.
Archives of Dermatological Research
|
June 8, 2024
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Kim A Papp, Melinda Gooderham, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery
|
August 12, 2023
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, et al.
Dermatology and Therapy
|
May 2, 2024
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Eric L Simpson, Vimal H Prajapati, Yael A Leshem, et al.
Pediatric Dermatology
|
February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial
Lawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
JAMA Dermatology
|
October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks
Amy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.
The Journal of Dermatological Treatment
|
June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary
Eric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology
|
September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
Eric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
JAMA Dermatology
|
April 12, 2023
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials
Amy S Paller, Barry Ladizinski, Pedro Mendes-Bastos, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 105) with videos related to
Sort By:
Page
of 11
Dermatology and Therapy
|
March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
Kim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Dermatology and Therapy
|
June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis
Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.
Archives of Dermatological Research
|
June 8, 2024
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry
Kim A Papp, Melinda Gooderham, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery
|
August 12, 2023
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, et al.
Dermatology and Therapy
|
May 2, 2024
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Eric L Simpson, Vimal H Prajapati, Yael A Leshem, et al.
Pediatric Dermatology
|
February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial
Lawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
JAMA Dermatology
|
October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks
Amy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.
The Journal of Dermatological Treatment
|
June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary
Eric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
JAMA Dermatology
|
September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
Eric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
JAMA Dermatology
|
April 12, 2023
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials
Amy S Paller, Barry Ladizinski, Pedro Mendes-Bastos, et al.
Page
of 11